Citius Pharmaceuticals Inc (NAS:CTXR)

$ 3.68 0.37 (11.18%) Market Cap: 28.44 Mil Enterprise Value: 8.59 Mil PE Ratio: 0 PB Ratio: 0.31 GF Score: 31/100

Citius Pharmaceuticals Inc at Sidoti & Company January Micro-Cap Virtual Conference Transcript
Jan 18, 2023
Citius Pharmaceuticals Inc at ThinkEquity Conference Transcript
Oct 26, 2022
Citius Pharmaceuticals Inc at Dawson James Small Cap Growth Conference Transcript
Oct 12, 2022
Citius Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
Citius Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Apr 20, 2022
Citius Pharmaceuticals Inc at Benzinga Virtual Global Small Cap Conference Transcript
May 13, 2021
Citius Pharmaceuticals Inc Corporate Analyst Meeting Transcript
Dec 06, 2020
Citius Pharmaceuticals Inc CEORoadshow Interview with Leonard Mazur Transcript
Jul 10, 2020
Citius Pharmaceuticals Inc at Noble Capital Markets Small and Microcap Investor Conference Transcript
Feb 16, 2020

Citius Pharmaceuticals Inc at Noble Capital Markets Investor Conference (Virtual) Transcript

Apr 20, 2022 / 05:30PM GMT

Release Date Price: $34 (+4.21%)

Transcript

Leonard Mazur

Citius Pharmaceuticals, Inc. - Co-Founder, CEO, and Chairman

Good afternoon, everybody. Thank you for taking the time out to attend our presentation. I'm Leonard Mazur, I'm the Chairman and CEO of Citius Pharmaceutical.

And just bring your attention to -- I'm going to be making forward-looking statements here. What I advise everyone all the time is, please consult the sec.gov for all the up-to-date information. All our filings are located there, or alternatively citiuspharma.com, which is our website.

So, give you a little bit of a background on the company and the history of it. Myself and Myron Holubiak the -- is now the Executive Vice Chair of the company, we actually formed a private company first back in 2013. And that private company was formed to in-license a drug, our first drug that we have, which is Mino-Lok from M.D. Anderson. We did that successfully and funded all of the initial Phase 2b work personally, ourselves at the time.

And then in 2016, we decided that we had to really -- we had a merging with a public company because we began to recognize

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.